BIIB094 Trial Reports Safety And CSF LRRK2 Reduction

Authors report that BIIB094, an antisense oligonucleotide tested in people with Parkinson disease, was generally well tolerated in a first-in-human, multi-center clinical trial. They also describe lower cerebrospinal fluid LRRK2 protein levels among treated participants, pairing early safety observations with a biomarker signal. The trial evaluated whether BIIB094 could safely reduce LRRK2 levels in people with Parkinson disease, without extending claims to measured clinical improvement outcomes. Authors described the enrolled population as people with Parkinson disease undergoing initial evaluation of the agent in a multi-center research setting. The readout centered on tolerability and target engagement, rather than on changes in symptoms, cognition, movement, or disease progression.

Investigators describe a randomized, placebo-controlled trial that enrolled 82 participants across two study segments designed to test initial dosing approaches for BIIB094. In one segment, participants received a single dose of BIIB094 or placebo. In the other, participants received four doses, with administration scheduled every four weeks. Investigators state that administration was intrathecal, with dosing delivered through lumbar puncture directly into the cerebrospinal fluid. Taken together, the two segments laid out the control structure, dose timing, and delivery method within the first-in-human development design.

The study notes that treatment was generally well tolerated during the reported observation period. Adverse events were described as common but mostly mild to moderate in severity. Investigators found that these events did not limit dosing during the study, allowing planned schedules to proceed as intended. They also reported no serious adverse events related to BIIB094 during the reported trial period. This summary reflects how the study team described safety findings in this early clinical evaluation.

Researchers observed that cerebrospinal fluid analysis showed LRRK2 protein reductions of up to 59 percent in treated participants overall. They added that these reductions were described regardless of whether participants carried a known LRRK2 mutation. The investigators said the trial was not designed to assess clinical benefits involving movement, cognition, or disease progression. They described a larger phase 2 study as the next step, focused on efficacy—including whether the therapy might slow disease progression—using motor assessments and standard Parkinson’s rating scales.

Key Takeaways

• A randomized, placebo-controlled study reported one single-dose segment and one four-dose segment delivered intrathecally through lumbar puncture.
• BIIB094 was reported as generally well tolerated, with adverse events mostly mild to moderate and no serious BIIB094-related adverse events.
• Cerebrospinal fluid LRRK2 protein reductions of up to 59 percent were observed, and investigators said efficacy assessment is planned for phase 2.